Hjem › Multipelt myelom › Louisiana
Kliniske studier for Multipelt myelom i Louisiana
9 studier for Multipelt myelom søker deltakere på steder i Louisiana.
Byer i Louisiana
Offisiell studietekst (engelsk)
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Local Institution - 0385, Shreveport
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT05519085A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- LSU Health Feist Weiller Cancer Center, Shreveport
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07518186Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
- Mary Bird Perkins Cancer Center, Baton Rouge
RekruttererFase 4
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07609940A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- LSUHSC Shreveport Feist-Weiller Cancer Center, Shreveport
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT05552222A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Pontchartrain Cancer Center, Covington
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 24. sep. 2026 · NCT07477587A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Louisiana State University Health Sciences Shreveport, Shreveport
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT06615479A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Baton Rouge
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. aug. 2026 · NCT07227311Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Baton Rouge
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 14. aug. 2026 · NCT07764978A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Tulane University School of Medicine /ID# 251204, New Orleans
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 13. jul. 2026 · NCT05650632Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.